Omada Health, Inc.
Omada Health (NASDAQ:OMDA) presented a 12-week study at the World Obesity and Weight Management Congress, showing its GLP-1 Care Track program led to 6.0% average weight loss vs. 3.3% for usual care. The study, published in Diabetes, Obesity and Metabolism, involved 245 adults with obesity. Omada's program also improved body composition, well-being, and reduced depression/anxiety symptoms.
Freedom Capital Markets reiterated a Buy rating and $35 price target for Omada Health, implying a 91.3% upside. The firm cites strong demand for Omada's integrated care solutions and resilience against competitors.
Omada Health (Nasdaq: OMDA) will release its Q3 2026 results on Nov. 5 after market close and host a conference call at 4:30 p.m. ET. The call will be webcast live and a replay will be available for 12 months. Omada Health is a virtual healthcare provider focusing on chronic conditions.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning OMDA (Omada Health, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent OMDA coverage spans earnings, financial news and insider activity.
In the last 30 days, OMDA insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($357K). The most active reporter was Duffy Sean P., Chief Executive Officer, with 2 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Positive clinical data may boost investor confidence in Omada's digital weight‑loss platform.
Freedom Capital Markets reiterated a Buy rating and $35 price target for Omada Health, implying a 91.3% upside. The firm cites strong demand for Omada's integrated care solutions and resilience against competitors.
The announcement sets the timeline for the upcoming earnings report, which may drive short-term trading interest around the release.
Insider sale may signal weak confidence, modest negative pressure on the stock.
Raised guidance and record margins suggest improving unit economics and profitability trajectory, but management flagged H2 growth moderation and potential GLP-1 coverage pullbacks.
AlphAI scores every news story that mentions OMDA with an AI model for sentiment and relevance, and aggregates insider trades from Omada Health, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Omada Health (NASDAQ:OMDA) presented a 12-week study at the World Obesity and Weight Management Congress, showing its GLP-1 Care Track program led to 6.0% average weight loss vs. 3.3% for usual care. The study, published in Diabetes, Obesity and Metabolism, involved 245 adults with obesity. Omada's program also improved body composition, well-being, and reduced depression/anxiety symptoms.
2 min readFreedom Capital Markets reiterated a Buy rating and $35 price target for Omada Health, implying a 91.3% upside. The firm cites strong demand for Omada's integrated care solutions and resilience against competitors.
1 min readOmada Health (Nasdaq: OMDA) will release its Q3 2026 results on Nov. 5 after market close and host a conference call at 4:30 p.m. ET. The call will be webcast live and a replay will be available for 12 months. Omada Health is a virtual healthcare provider focusing on chronic conditions.
1 min readDuffy Sean P. (Chief Executive Officer) sold 21,572 shares of Omada Health, Inc. (OMDA) at an average of $23.62 ($23.12–$24.27, $0.51M total) across 4 trades on 2026-09-01 under a Rule 10b5-1 trading plan.
1 min readOmada Health (OMDA) reported Q2 2026 revenue of $88 million, up 43% year over year, with GAAP gross margin of 73% and GAAP net income of $5 million. Adjusted EBITDA was $11 million. The company raised full-year revenue guidance to $334 million to $340 million and adjusted EBITDA to $21 million to $27 million, citing member growth and lower cost to serve.
6 min readDuffy Sean P. (Chief Executive Officer) sold 21,570 shares of Omada Health, Inc. (OMDA) at an average of $23.62 ($20.90–$24.81, $0.51M total) across 3 trades over 2026-08-07 to 2026-08-10 under a Rule 10b5-1 trading plan.
2 min readOmada Health (NASDAQ:OMDA) reported record Q2 performance, with growth driven by demand for GLP-1-related programs and broader diabetes and hypertension offerings, according to CEO Cook. Trailing 12-month revenue per member rose 2% to $284. Omada targets 20%+ revenue growth and 70%+ gross margin, and is expanding with CVS, Optum and HCSC.
6 min readOmada Health, which went public in June, said Wei-Li Shao will become CEO on Jan. 1, replacing founder Sean Duffy, who will move to executive chair. The change was announced with Q2 results. Omada reported Q2 revenue of $88 million (+43% Y/Y), profit of $5 million, gross margin of 73%, and raised 2026 revenue guidance to $334 million-$340 million.
4 min readOmada Health, Inc. (OMDA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Omada Health Reports Second Quarter 2026 Results and Announces CEO Transition • Revenue Grew 43% and Total Members Increased 45% Year over Year, with Gross Margin Reaching a New Quarterly Record • Company Announces Sean Duffy to Become Executive Chair and Wei-Li Shao to Become Ch
6 min readCook Steven L. (Chief Financial Officer) sold 35,600 shares of Omada Health, Inc. (OMDA) at an average of $22.87 ($22.76–$23.09, $0.81M total) across 2 trades over 2026-07-01 to 2026-07-07 under a Rule 10b5-1 trading plan.
1 min read
